Valuation: Quanterix Corporation

Market Cap 182M 159M 147M 135M 255M 17.53B 261M 1.75B 690M 8.59B 684M 669M 29.56B P/E 2026 *
-3x
P/E 2027 * -2.92x
Enterprise Value 182M 159M 147M 135M 255M 17.53B 261M 1.75B 690M 8.59B 684M 669M 29.56B EV / Sales 2026 *
1.07x
EV / Sales 2027 * 0.96x
Free-Float
93.7%
Yield 2026 *
-
Yield 2027 * -
1 day-2.40%
1 week-0.39%
Current month-10.53%
1 month+14.01%
3 months+10.43%
6 months-47.77%
Current year-39.23%
1 week 3.7
Extreme 3.695
4.42
1 month 3.18
Extreme 3.18
4.57
Current year 2.4
Extreme 2.395
8.77
1 year 2.4
Extreme 2.395
8.77
3 years 2.4
Extreme 2.395
29.7
5 years 2.4
Extreme 2.395
60.92
10 years 2.4
Extreme 2.395
92.57
Manager TitleAgeSince
Chief Executive Officer 59 2026-01-18
Director of Finance/CFO 50 2026-06-21
Chief Operating Officer - 2026-05-13
Director TitleAgeSince
Director/Board Member 63 2022-06-05
Chairman 64 2025-03-23
Director/Board Member 48 2024-08-18
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Fiscal year

Chief Technology Officer

3,583 0.0077%
7/15/26 Free

Chief Financial Officer

141,820 0.3052%
7/8/26 Fiscal year

Director

16,146 0.0347%
Change 5-day change 1-year change 3-year change Capi.($)
-2.40%-0.39%-28.03%-84.36% 182M
-1.97%+1.03%+28.39%-0.57% 198B
-0.58%+2.40%+7.25%-16.42% 144B
-14.15%-15.08%-33.40%-1.22% 122B
-1.32%-1.65%-57.52%-15.88% 65.44B
-2.40%-7.03%+12.08%-6.43% 49.36B
-0.11%+1.53%-23.83%-31.33% 44.74B
-3.41%-2.11%+15.33%+6.81% 37.13B
-2.44%-1.98%+28.33%+31.74% 36.23B
-1.86%-2.39%-22.85%-8.74% 28.7B
Average -3.10%-2.57%-7.43%-12.64% 72.63B
Weighted average by Cap. -3.72%-2.62%-0.99%-5.86%

Financials

2026 *2027 *
Net sales 170M 148M 137M 126M 238M 16.36B 243M 1.64B 644M 8.01B 638M 624M 27.58B 189M 165M 152M 140M 264M 18.17B 270M 1.82B 715M 8.9B 709M 693M 30.64B
Net income -61.09M -53.39M -49.27M -45.41M -85.59M -5.88B -87.49M -589M -232M -2.88B -229M -224M -9.92B -63.78M -55.74M -51.44M -47.41M -89.36M -6.14B -91.35M -615M -242M -3.01B -240M -234M -10.36B
Net Debt - -
Logo Quanterix Corporation
Quanterix Corporation is a life sciences company. The Company is focused on ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development proprietary digital Simoa detection technology enables customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. Its Simoa bead-based digital immunoassays utilize the basic principles of conventional bead-based sandwich ELISA. The HD-X is the Company's flagship instrument that empowers biomarker research and accelerates drug development. Its SR-X instrument is a compact benchtop instrument with a lower price point, more flexible assay preparation, and a wider range of applications. The Company's Spatial Biology solutions measure protein expression and cellular phenotypes within intact tissue while preserving spatial context and tissue architecture.
Employees
450
Date Price Change Volume
26-07-17 US$3.865 -2.40% 529,119
26-07-16 US$3.960 -6.60% 1,020,737
26-07-15 US$4.240 +3.92% 639,503
26-07-14 US$4.080 +5.15% 584,745
26-07-13 US$3.880 0.00% 289,605
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
3.865USD
Average target price
4.333USD
Spread / Average Target
+12.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. QTRX Stock